Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021054806 - PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING

Publication Number WO/2021/054806
Publication Date 25.03.2021
International Application No. PCT/KR2020/012721
International Filing Date 21.09.2020
IPC
C12N 5/0793 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
079Neural cells
0793Neurons
A61K 35/30 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
A61P 25/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
CPC
A61K 35/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
A61P 25/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
C12N 2501/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
10Growth factors
11Epidermal growth factor [EGF]
C12N 2501/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
10Growth factors
115Basic fibroblast growth factor (bFGF, FGF-2)
C12N 2501/119
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
10Growth factors
119Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
C12N 2501/15
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
10Growth factors
15Transforming growth factor beta (TGF-β)
Applicants
  • 한국생명공학연구원 KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR]/[KR]
Inventors
  • 김장환 KIM, Janghwan
  • 이민형 LEE, Minhyung
  • 손미영 SON, Mi Young
  • 전영주 JEON, Young Joo
  • 백아름 BAEK, Areum
  • 이영전 LEE, Young Jeon
  • 서진철 SEO, Jincheol
  • 정초록 JUNG, Cho Rok
Agents
  • 제일특허법인(유) FIRSTLAW P.C.
Priority Data
10-2019-011625820.09.2019KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING
(FR) PROCÉDÉ DE PRODUCTION DE PROGÉNITEURS NEURONAUX DOPAMINERGIQUES INDUITS PAR REPROGRAMMATION DIRECTE
(KO) 직접 리프로그래밍을 통한 유도 도파민성 신경세포 전구체의 제조방법
Abstract
(EN) The present invention relates to a method for producing induced dopaminergic neuronal progenitors from adult cells using direct reprogramming, induced dopaminergic neuronal progenitors produced via the method and a use for same, wherein, as a result of having been directly reprogrammed from adult cells, the induced dopaminergic neuronal progenitors produced by means of the present invention can be transplanted inside a living body without the risk of oncogenicity, and have excellent proliferative capacity and dopaminergic neuronal differentiation potency, thus can be usefully utilized as a cell therapy product for Parkinson's disease.
(FR) La présente invention concerne un procédé de production de progéniteurs neuronaux dopaminergiques induits à partir de cellules adultes au moyen d'une reprogrammation directe, des progéniteurs neuronaux dopaminergiques induits produits par l'intermédiaire du procédé et une utilisation de ceux-ci, les progéniteurs neuronaux dopaminergiques induits produits au moyen de la présente invention pouvant, en conséquence d'avoir été directement reprogrammés à partir de cellules adultes, être transplantés à l'intérieur d'un corps vivant sans risque d'oncogénicité, et ayant une excellente capacité de prolifération ainsi qu'une excellente puissance de différenciation neuronale dopaminergique, et pouvant donc être utilisés de manière utile en tant que produit de thérapie cellulaire pour la maladie de Parkinson.
(KO) 본 발명은 성체세포로부터 직접 리프로그래밍을 통하여 유도 도파민성 신경세포 전구체를 제조하는 방법과 이를 통하여 제조된 유도 도파민성 신경세포 전구체 및 이의 용도에 관한 것으로, 본 발명에 의해 제조된 유도 도파민성 신경세포 전구체는 성체세포로부터 직접 리프로그래밍 되므로 종양원성의 위험 없이 생체 내 이식이 가능하며, 증식능 및 도파민성 신경세포로의 분화능이 우수하여 파킨슨병의 세포 치료제로서 유용하게 활용될 것이다.
Related patent documents
JP2022517879This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau